Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200-a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
ophthalmologytimes22h
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...
Outlook falls 10% on ONS-5010 update, warrant inducements
Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...